Literature DB >> 484237

Activation of human monocytes by mediators from lymphocytes stimulated with Corynebacterium parvum.

J Hammerström, G Unsgaard, J Lamvik.   

Abstract

Human monocytes activated in vitro by lymphokine-containing supernatants of autologous or allogeneic lymphocytes stimulated in vitro by Corynebacterium parvum (CP) expressed increased ability to suppress DNA-synthesis in a human tumour cell line. Monocyte activation was not dependent on in vitro differentiation of monocytes, enhanced cytostatic ability being observed at all stages of in vitro differentiation. The lymphokine-induced cytostatic ability was not affected by intensive washing and trypsin treatment of the activated monocytes, but disappeared during 48 hours of in vitro culture of the activated cells. The increased cytostatic ability of lymphokine-activated monocytes did not seem to be due to stable supernatant factors released from monocytes. CP stimulated DNA-synthesis in peripheral blood lymphocytes of 28 normal donors, thus confirming the mitogenic effect of CP on human lymphocytes. Lymphokine production in response to CP correlated with the magnitude of DNA-synthesis, but appeared before DNA-synthesis could be detected in the lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 484237

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Scand C        ISSN: 0304-1328


  4 in total

1.  Production of an anti-tumour cytotoxin by human monocytes.

Authors:  N Matthews
Journal:  Immunology       Date:  1981-09       Impact factor: 7.397

2.  Physicochemical characterization of cytostatic factors released from human monocytes.

Authors:  J Nissen-Meyer; J Hammerstrøm
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

3.  Study of cytotoxicity against adenovirally transformed cells in patients with tumours of the urinary tract.

Authors:  I Romics; J Horváth
Journal:  Int Urol Nephrol       Date:  1986       Impact factor: 2.370

4.  Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates.

Authors:  A Nakagawara; N M DeSantis; N Nogueira; C F Nathan
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.